Bagheri Narges, Montazeri Hesam
Department of Applied Mathematics, University of Azarbaijan Shahid Madani, Tabriz, Iran.
Department of Bioinformatics, Institute of Biochemistry and Biophysics (IBB), University of Tehran, Tehran, Iran.
SN Compr Clin Med. 2021;3(6):1261-1271. doi: 10.1007/s42399-021-00835-1. Epub 2021 Mar 15.
Bacille Calmette-Guérin (BCG) vaccine has been globally used to protect infants against tuberculosis (TB) for about a century. This vaccine has been shown to provide some degree of non-specific protection from other respiratory tract infections. This advantage has encouraged researchers to investigate the potential protection of this vaccine from the coronavirus disease 2019 from different perspectives in the ongoing pandemic. In this study, we have comprehensively reviewed the latest articles on potential vaccine effectiveness of BCG on COVID-19 and summarized the possible impacts of the BCG against SARS-COV-2 in detail.
卡介苗(BCG)疫苗在全球范围内用于保护婴儿免受结核病(TB)侵害已有约一个世纪。已证明这种疫苗能提供一定程度的针对其他呼吸道感染的非特异性保护。这一优势促使研究人员在当前大流行中从不同角度研究这种疫苗对2019冠状病毒病的潜在保护作用。在本研究中,我们全面回顾了关于卡介苗对COVID-19潜在疫苗效力的最新文章,并详细总结了卡介苗对严重急性呼吸综合征冠状病毒2(SARS-CoV-2)的可能影响。